Palazzuoli, A;
Del Buono, MG;
La Vecchia, G;
Greene, SJ;
Ambrosy, AP;
Chioncel, O;
Gustafsson, F;
Krim, SR;
Lavie, CJ;
Adamo, M;
et al.
Palazzuoli, A; Del Buono, MG; La Vecchia, G; Greene, SJ; Ambrosy, AP; Chioncel, O; Gustafsson, F; Krim, SR; Lavie, CJ; Adamo, M; Gal, TB; Geavlete, O; Antohi, L; Rosano, G; Collins, S; Crea, F
(2025)
Worsening versus advanced heart failure: Management and challenges.
ESC Heart Failure.
ISSN 2055-5822
https://doi.org/10.1002/ehf2.15437
SGUL Authors: Rosano, Giuseppe Massimo Claudio
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (1MB) |
|
|
Microsoft Word (.docx) (Table S1)
Supporting information
Download (13kB) |
Abstract
Heart failure (HF) is a progressive condition marked by recurrent episodes of symptom exacerbation, leading to worsening cardiac function, increased hospitalization and mortality risk. Worsening HF (WHF) and advanced HF (AdvHF) represent two distinct stages in this progression, each with unique clinical features and therapeutic needs. WHF is characterized by a deterioration of pre‐existing symptoms requiring intensified treatment, such as diuretic escalation, which often reflects disease progression. Conversely, AdvHF involves severe cardiac dysfunction with persistent symptoms despite optimal medical management, requiring advanced interventions such as inotropic support or heart transplant. Although both stages share some pathophysiological and clinical features, they differ significantly in haemodynamic profiles, disease severity and response to treatment. This review argues that recognizing the transition from WHF to AdvHF is a pivotal issue in patient care. We explore the distinct natural histories, clinical presentations and diagnostic markers of WHF and AdvHF to provide a framework for earlier, more targeted interventions aimed at altering the disease trajectory and preventing the decline associated with the advanced stage. While WHF symptoms are typically reversible with appropriate interventions, AdvHF represents the end stage of HF with often irreversible dysfunction and multi‐organ involvement. A clearer understanding and standardized definition of these phenotypes are essential for improving patient outcomes and guiding future clinical research.
| Item Type: | Article | ||||||
|---|---|---|---|---|---|---|---|
| Additional Information: | © 2025 The Author(s). ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | ||||||
| Keywords: | advanced heart failure, hospitalization, management, outcome, worsening heart failure | ||||||
| SGUL Research Institute / Research Centre: | Academic Structure > Cardiovascular & Genomics Research Institute Academic Structure > Cardiovascular & Genomics Research Institute > Experimental Cardiology |
||||||
| Journal or Publication Title: | ESC Heart Failure | ||||||
| ISSN: | 2055-5822 | ||||||
| Language: | en | ||||||
| Media of Output: | Print-Electronic | ||||||
| Related URLs: | |||||||
| Publisher License: | Creative Commons: Attribution 4.0 | ||||||
| PubMed ID: | 41045229 | ||||||
| Dates: |
|
||||||
| Go to PubMed abstract | |||||||
| URI: | https://openaccess.sgul.ac.uk/id/eprint/118020 | ||||||
| Publisher's version: | https://doi.org/10.1002/ehf2.15437 |
Statistics
Actions (login required)
![]() |
Edit Item |

